Therapeutic CD94/NKG2A blockade with an anti-NKG2A monoclonal blocking antibody, monalizumab, restored direct cytotoxicity of NK cells against chronic lymphoid leukemia cells in vitro (97). Here, KLRC1 is linked to lymphoid leukemia.